Business
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE,
About this update from Agios Pharmaceuticals, Inc.
[{"type":"text","content":"– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation –\n – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that mitapivat and ivosidenib clinical data will be presented at the European Hematology Association (EHA) Annual Congress being held virtually June 11-14, 2020. The accepted abstracts are listed below and are available online on the EHA meeting library website: https://eha25-eha.web.indrina.com/abstracts. All presentations can be accessed on demand by registered meeting attendees on the EHA Virtual Congress platform as of Friday, June 12 at 08:30 a.m. CEST / 2:30 a.m. ET and will be accessible until October 15, 2020. Oral Presentation: Title: Proof of concept for the oral pyruvate kinase activator mitapivat in adults with non-transfusion-dependent thalassemia: Interim results from an ongoing, phase 2, open-label, multicenter studyDate & Time: Friday, June 12, 2020 at 8:30 a.m. CEST / 2:30 a.m. ETOral Abstract Session: New therapeutic approaches for thalassemia Abstract: S297Presenter: Kevin H. M. Kuo, M.D., Toronto General Hospital Poster Presentations: Title: Mitapivat (AG-348) long-term safety and efficacy in pyruvate kinase deficiency: 3-year results of the Drive PK studyPoster Session: Enzymopathies, membranopathies and other anemiasAbstract: EP1561Author: Rachael F. Grace, M.D., Boston Children’s Hospital Title: Ivosidenib improves overall survival relative to standard therapies in relapsed or refractory mutant IDH1 AML: Results from matched comparisons to historical controlsPoster Session: Acute myeloid leukemia - ClinicalAbstract: EP540Author: Peter Paschka, M.D., Universitätsklinikum Ulm Title: Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment of a phase 1 dose escalation and expansion studyPoster Session: Myelodysplastic syndromes - Clinical Abstract: EP826Author: Courtney D. DiNardo, M.D., University of Texas MD Anderson Cancer Center Title: Pharmacokinetic/pharmacodynamic evaluation of ivosidenib or enasidenib combined with intensive induction and consolidation chemotherapy in patients with newly diagnosed...